Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy

Blood

Volumn 113, Issue 7, 2009, Pages 1412-1421

  Illidge, Tim M ^a   Bayne, Mike ^b,c   Brown, Nicholas S ^a   Chilton, Samantha ^c   Cragg, Mark S ^c   Glennie, Martin J ^c   Du, Yong ^d   Lewington, Valerie ^e,f   Smart, James ^c   Thom, James ^f   Zivanovic, Maureen ^g   Johnson, Peter W M ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; NEUTROPENIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SEPSIS; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 61849136656     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175653     Document Type: Article

References (48)

1. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005; 80:1087-1097.
2. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
3. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
4. Herold MG, Dolken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol. 2003;82:77-79.
5. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
6. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmuno-therapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103: 4429-4431.
7. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
8. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
9. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696-5704.
10. 90Y Ibritumomab tiuxetan after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156-5164.
11. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45-Ab. Blood. 2008;112:830-835.
12. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem cell rescue. J Clin Oncol. 1998;16: 3270-3278.
13. Kennel SJ. Effects of target antigen competition on distribution of monoclonal antibody to solid tumors. Cancer Res. 1992;52:1284-1290.
14. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82:763-771.
15. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer. 1998;94:1332-1348.
16. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
17. Sohaib SA, Turner B, Hanson JA, et al. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol. 2000;73: 1178-1184.
18. Cragg MS, Bayne MB, Tutt AL, et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood. 2004;104: 2540-2542.
19. Markwell MAK. A new solid-state reagent to iodinate proteins: conditions for the efficient labelling of antiserum. Anal Biochem. 1982;125:427-432.
20. Wahl RL, Kroll S, Zasadny KR. Patient specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(suppl):14S-20S.
21. Howell RW, Wessels BW, Loevinger R, et al. The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med. 1999; 40(suppl):3S-10S.
22. Wahl RL. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol. 2003;30: 31-38.
23. Kaminski MS, Estes J, Zasadny KR, et al. Radio-immunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
24. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
25. US National Institutes of Health. CTCAE/CTC Archive. http://ctep.info. nih.gov/reporting/ctc-archive.html. Accessed May 25, 2008.
26. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
27. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
28. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J Clin Oncol. 1999;17: 1851-1857.
29. Press OW, Farr AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49:4906-4912.
30. Smith MR. Rituximab (anti-CD20 monoclonal antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
31. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44:3823-3837.
32. Cragg MS, Morgan SM, Chan HTC, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045-1052.
33. Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007;179:4263-4271.
34. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood. 2008;111:1456-1463.
35. 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med. 2002;29: 1276-1282.
36. Antonescu C, Bischof-Delaloye A, Kosinski M, et al. Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics. Eur J Nucl Med Mol Imaging. 2005;32: 943-951.
37. Boucek JA, Turner JH. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:458-469.
38. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmuno-therapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
39. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmuno-therapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
40. Wahl RL. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med. 2005; 46(suppl 1):128S-140S.
41. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmuno-therapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
42. Pagel JM, Pantelias A, Hedin N, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radio-immunotherapy of B-cell lymphomas. Cancer Res. 2007;67:5921-5927.
43. Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol. 2005;23:579s. Abstract 6577.
44. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348:2691-2694.
45. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
46. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
47. Press OW, Rasey J. Principles of radioimmuno-therapy for hematologists and oncologists. Semin Oncol. 2000;27:62-73.
48. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lym-phoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108: 3295-3301.